首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer
【24h】

Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

机译:在接受三联肝动脉输注和西妥昔单抗静脉源性治疗的野生型KRAS结直肠癌肝转移患者中,先前接受治疗的患者的早期肿瘤反应可作为生存预测指标

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Early tumour shrinkage has been associated with improved survival in patients receiving cetuximab-based systemic chemotherapy for liver metastases from colorectal cancer (LM-CRC). We tested this hypothesis for previously treated LM-CRC patients receiving cetuximab (500 mg/m(2)) and triplet hepatic artery infusion(HAI) within European trial OPTILIV.
机译:背景:早期肿瘤缩小与接受基于西妥昔单抗的全身化疗的大肠癌肝转移患者的生存期改善有关。我们在欧洲试验性OPTILIV中对接受西妥昔单抗(500 mg / m(2))和三联肝动脉输注(HAI)的先前治疗的LM-CRC患者进行了这一假设检验。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号